The pharmacological basis for application of cannabidiol in cancer chemotherapy

Margarita Zhelyazkova¹, Bogdan Kirilov¹, Georgi Momekov²

¹ Bulgarian Drug Agency, Sofia, Bulgaria
² Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Corresponding author: Georgi Momekov (gmomekov@gmail.com)

Received 20 February 2020 ♦ Accepted 14 March 2020 ♦ Published 23 October 2020

Citation: Zhelyazkova M, Kirilov B, Momekov G (2020) The pharmacological basis for application of cannabidiol in cancer chemotherapy. Pharmacia 67(4): 239–252. https://doi.org/10.3897/pharmacia.67.e51304

Abstract

Chemotherapy is one of the therapeutic approaches for cancer treatment and has demonstrated great success with the introduction of selectively acting molecules against specific biomarkers of some types of tumors. Despite this success there is a large unmet need for novel therapies that provide effective control on the progression of advanced or drug-resistant cancer diseases. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, as possible agents for cancer therapy. We analyzed the anticancer properties and mechanism of action of cannabidiol (CBD), the main non-psychoactive cannabinoid received from hemp of Cannabis plant. Despite of data for pleiotropic effects of CBD, we here present the results for the efficacy of CBD in the modulation of different stages of cancer development. The analysis of the anticancer properties of CBD is made in relation to the proposed or newly discovered molecular targets of action. Thereafter, we consider the specific effects of CBD on primary tumors, their invasiveness and metastases, whether the influence on identified tumor markers in different types of tumors reflect the therapeutic potential of CBD. The studies reviewed herein indicate that CBD elicit activity through the cannabinoid receptor dependent and independent pathways. The processes such as ceramide production, ER-stress, autophagy and apoptosis, angiogenesis and matrix remodeling also appear to regulate the anticancer activity of CBD. So, the pharmacological basis for therapeutic application of CBD is constructed on the scientific data for its antitumor activity, extensively provided studies in vitro and in vivo in animal tumor models, and available data on the safety profile of clinically approved CBD products. We also try to reduce the deficits of our understanding in relation of pharmacological synergistic interactions of CBD with cytostatic drugs, where data remains limited. It is recognized that more studies for defining the specific molecular and signaling mechanisms of anticancer action of cannabinoids, particularly CBD, requires further evaluation. We believe that the therapeutic advantages of CBD are associated not only with its non-psychoactive behavior, but also are related to its influence on the important biochemical pathways and signal molecules, defining the genome instability and specific changes of the malignant tumor cells.

Keywords

anticancer effect, cannabidiol, mechanism of action, pharmacological interactions, safety profile

Introduction

In the recent decade many investigators have been trying to establish a scientific base for the therapeutic application of cannabinoids for different diseases including malignant tumors. Interest in the anticancer properties of cannabinoids was renewed after the discovery of the Endocannabinoid system (ECS) which was realized with
the cloning of specific cannabinoid receptors (Zou and Kumar 2018). The ECS is a signalling system comprising the cannabinoid CB1 and CB2 receptors, their intrinsic lipid ligands, endocannabinoids, and the associated transporters, biosynthetic and degradative enzymes. Both cannabinoid receptors are G protein-coupled receptors: CB1 are highly distributed in the central nervous system (CNS), with low to moderate expression in the periphery, whereas CB2 receptors are high in the immune system, and have a moderate expression in other tissues, including the cardiovascular system, gastro-intestinal tract, liver, adipose tissue, bone, and reproductive system (Howlett et al. 2002). Two major known endogenous ligands are the anandamide (AEA) and the 2-arachidonoylglycerol (2-AG). Both are arachidonic acid derivatives produced from phospholipid precursors through activity-dependent mechanism of specific phospholipase enzymes. Apart from their binding to CB1 and CB2 receptors, they may bind to other receptors as the vanillioid receptor type 1 (TRPV1); the ‘orphan’ G protein-coupled receptor, GPR55, and the peroxisome proliferator-activated receptor, PPAR (Kano et al. 2009).

In 1975 Munson et al. (1975) obtained that Tetrahydrocannabinol (Δ9-THC, THC) and Cannabidiol (CBD), the main cannabinoids in *Marijuana sativa* inhibit the growth of Lewis lung carcinoma after oral administration in mice. Since then the anti-proliferative and pro-apoptotic effects of several natural and synthetic cannabinoids in cancer cell lines and in some cases in animal tumor models were evaluated (Galve-Roperh et al. 2000; Sánchez et al. 2001; Casanova et al. 2003; Blázquez et al. 2006). Moreover, studies showed the potential of these compounds to inhibit tumor invasion, cell migration and metastasis (Freimuth et al. 2010). However, the clinical use of THC and synthetic agonists of the cannabinoid receptors is limited by their unwanted psychoactive side effects. So, this area of research is quite controversial and debatable. The interest of the researchers is now oriented to several phytocannabinoids, which have no psychoactive effects, especially CBD. It was suggested that they may be used in various pathological conditions, including inflammation and pain, cytostatic-induced emesis, cancer, narcotic addiction and epilepsy (Izzo et al. 2009; Grotenhermen and Muller-Vahl 2012). Review data of Massi et al. (2013) focus on the efficacy of CBD in the modulation of tumor growth and progression in some general types of cancer as breast, lung, colon, and lympho-proliferative malignant diseases as one group. Additional data in the recent years gives us a reason to make predictable pharmacological analysis for tumor cytotoxicity and mechanisms of action of CBD in the context of its application alone or in combination with cytostatic drugs in cancer chemotherapy.

**Chemical structure**

As it is shown in figure 1, CBD is cyclohexene which is substituted by a methyl group at position 1, a 2,6-di-hydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4. It is a member of resorcinols, an olefinic compound, and a phytocannabinoid (Mechoulam and Hanus 2002). CBD is normally taken to refer as a naturally occurring (+)-enantiomer metabolite. (+) CBD has been synthesized, but received little attention because it has been shown to have only a modest affinity to CB1 and CB2 receptors unlike (-) CBD. Both of the enantiomer compounds inhibit anandamide hydrolysis and stimulate the vanillioid receptor type 1 (TRPV-1) at which capsaicin acts as well. The (+)-CBD isomer was more active than the (-)-CBD-isomer as an anticonvulsant agent in a mouse seizure model. However, to date, there is no substantive evidence as to whether (+)-CBD is likely to cause THC-like psychoactive effects.

Cannabidiol (INN) is the non-psychoactive compound derived from *Cannabis* species that has proposed therapeutic benefits. Cannabidiol is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant’s extract (Marks et al. 2009). The legal criteria for non-psychoactive hemp (also commonly-termed industrial hemp) is any part of the *Cannabis* plant, whether growing or not, which contain a ∆-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis, and CBD levels exceeding 10% by dry weight (State of Colorado 2018). Several industrial hemp varieties can be legally cultivated in Western Europe, and a variety such as „Fedora 17“ has a cannabinoid profile consistently around 1%, with THC less than 0.1%. The difference between marijuana and hemp is based on chemical composition, relates to the concentration of THC, the primary intoxicating compound found in *Cannabis*. Hemp is legally defined as a cultivar of *Cannabis sativa* with low concentrations of THC, although limitations on its concentrations differ internationally.

**Figure 1.** Chemical structures of ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), anandamide (AEA) and synthetic cannabinoid agonist WIN55212-2. Chemical name of CBD: 2-[(3R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol; IUPAC name: 2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylenbenzene-1,3-diol.
Safety profile and drug interactions

Cannabidiol is evaluated as well tolerated compound with a good safety profile. To date, there is no evidence of recreational use of CBD or any public health related problems to be associated with the use of pure CBD. Reviewed data of the World Health Organization for cannabis-related substances, including cannabidiol, are based on the evaluation of the Expert Committee on Drug Dependence (WHO 2017). These data show that CBD has no effect on a wide range of physiological and biochemical parameters or significant effects on animal behaviour unless extremely high doses are administered (more than 150 mg/kg IV as an acute dose or in excess of 30 mg/kg orally daily for 90 days in monkeys). The results from studies in humans and animals show, that CBD have very different effects from those of THC (Liffland and Grotenhermen 2017). In mice, CBD failed to produce the behavioral characteristics (e.g. suppression of locomotor activity, hypothermia, antinociception) associated with CB1 activation, whereas THC generate all of the effects which occur when CB1 is activated (Pertwee 2008; Izzo et al. 2009; Long et al. 2010). Tolerance to the effects of THC was observed, however no tolerance to CBD at any of the dosages was observed (Hayakawa et al. 2007). No studies of the physical dependence potential of CBD in animals were identified. It also failed to produce significant effects in a human study of abuse potential. Neuroimaging studies in humans and animals show that CBD has effects which are generally opposite to those of THC (Batalla et al. 2014). In contrast to THC, CBD has no effect on heart rate or blood pressure under normal conditions, but in animal models of stress CBD reduces heart rate and blood pressure (Sultan et al. 2017). CBD has no effect on embryonic development (limited research). Effects on the immune system are unclear; there is evidence of immune suppression at higher concentrations, but immune stimulation may occur at lower concentrations (Kaplan et al. 2008).

Adverse reactions are documented in clinical trials of Epidiolex (Cannabidiol, INN), and they are included in the characteristic of the product, approved for treatment of Dravet and Lennox-Gastaut syndromes which are both treatment-resistant seizure disorders (GW pharmaceuticals 2017). The clinical evaluation is based on a lot of data for a good safety profile. Rarely, the following are observed: drowsiness, tiredness, unusual lack of energy and decreased appetite, decreased weight, or diarrhea. A very serious allergic reaction to this drug is rare, but it is possible to have rash as a sign to stop the treatment. A small number of people who take anti-seizure drugs for any condition (such as seizure, bipolar disorder, pain) may experience depression, suicidal thoughts/attempt, or other mental/mood problems (Bergamaschi et al. 2011). Many of these reactions are due to possible interactions of CBD with a simultaneously received antiepileptic drug, as it is shown below.

Cannabinoids are metabolized with the cytochrome P450 enzyme system and inhibit predominantly the enzymes CYP3A4 and CYP2D6. THC and CBD have been found to inhibit CYP1A1, 1A2 and 1B1 enzymes during in vitro studies (Jiang et al. 2011; Stott et al. 2013). In addition CBD is a potent inhibitor of CYP3A4 and CYP2D6 (Geffrey AL et al. 2015). Theoretically, CBD may increase the blood concentration of many other medications received simultaneously. That is about 60% of all pharmaceuticals on the market, including common antipsychotics, anti-histamines, antiretrovirals, steroids, anticoagulants, and others. The summarized data for interactions of THC and CBD with some medications are presented in table 1. Many of these data are theoretical or derived from in vitro studies. Some of the interactions presented in the table are associated with smoked cannabis. These unwanted interactions may not be present with cannabis-based medicinal products when taken orally because oral products realize low bioavailability. It is known that cannabis products are contraindicated, or should not be used, in people with acute psychosis or unstable psychiatric conditions (Chetty et al. 1994), and in combination with benzodiazepines, opioids and phenobarbital (Rong et al. 2018). CBD may also interact with the ECS through direct or indirect mechanisms such as enhanced action of the anandamide. Then the inhibition of its enzymatic degradation was observed (Arellano et al. 2017).

| Table 1. Drug interactions with cannabinoids THC and CBD*. |
|-------------------------|-----------------|-----------------|
| Drugs                    | Effect of the Interaction | Research data   |
| Antiplatelets / anticoagulants | Increased risk of bleeding | In vitro studies found that THC and CBD may inhibit platelet aggregation. In a case study smoking cannabis significantly raised the INR of a patient prescribed warfarin after a mechanical heart valve replacement (Furmauk et al. 1989; Samrauerwegow et al. 2009) |
| Ketoconazole            | Increased concentration of CBD and THC | Ketoconazole inhibit CYP3A4, and increased the Cmax of CBD by 89% and THC by 27% Theoretically other inhibitors of CYP3A4 such as clarithromycin or itraconazole might increase the risk of adverse effects of CBD and THC (Stout et al. 2014) |
| Rifampicin              | Reduction of CBD and THC concentration | Rifampicin induce activity of CYP3A4 and reduce the Cmax of CBD by 52% and THC by 36% (Stout et al. 2014) |
| Anti-convulsants        | Increased levels of anticonvulsants and hepatotoxicity after valproates | CBD (Epidiolex®) increase bioavailability of topiramate, rufinamide, zonisamide. In addition AST/ALT levels were significantly increased in patients concurrently received valproate and CBD (Gaston TE et al. 2017; Vanreusenlow W et al. 2009) |
| Clobazam                | Increased concentration of clobazam | After four week treatment of children with clobazam and CBD are observed significant increasing of levels of its active metabolite nordclobazam and side effects such as drowsiness, ataxia and irritability at 77% of patients (Geffrey AL et al. 2015) |
| Phenobarbital           | Increased concentration of phenobarbital | Theoretically CBD as an inhibitor of CYP2C19 may increase plasma concentrations of phenobarbital (Rong C et al. 2018) |

*Theoretically, interactions of the cannabinoids with psycho-suppressive drugs, anticoagulants, antifungal, anti-diabetes and antiepileptic drugs are clinically important.

Target receptors and signal pathways

The identified molecular targets of CBD and other cannabinoids include numerous classical ion channels, receptors, transporters, enzymes, and newly identified signal
proteins (reviewed data of Katsidoni et al. 2013; Bih et al. 2015; Pyszniak et al. 2016). According to analysis of Bih et al. (2015) receptor targets of CBD account for only 15% of the known different molecular targets of cannabinoids described in the literature. But authors comment that many of these studies are provided at supraphysiological concentrations in vitro, rendering any contribution to behavioral effects unlikely. The recent evidence suggests that CBD has influence on cannabinoid CB1 receptor as a negative allosteric modifier of CB1 signaling, and can be used successfully for treatment of opioid abuse or THC intoxication (Straiker et al. 2018). CBD shows low affinity to CB2 receptors (McPartland et al. 2015). Despite of the limited data it has been proposed that ECS participates as a regulator of tumor cell malignancy, and the abnormal expression of CB receptors are defined in some tumors (Pyszniak et al. 2016). It is known that CB1 and/or CB2 receptors are coupled to several signaling pathways directly involved in cell survival, proliferation, and apoptosis, including p38 MAPK, cyclic AMP, PI3K-Akt, RhoA, JNK, EGF-R, ERK, and ceramide pathways (Sánchez et al. 1998; Cianchi et al. 2008). All cannabinoids induce sustained production of sphingolipid ceramide, which is commonly found in the cell membrane and is generated de novo by ceramide synthase or through sphingomyelin hydrolysis (Oesch and Gertsch 2009). Ceramide seems to be the key mediator of cannabinoid-mediated anticancer effects, as it is shown in osteosarcoma cells, glioma cells, and primary astrocytes through stimulation of ERK, MAPK, and/or JNK pathways (del Pulgar et al. 2002). In addition, there are several reports describing the influence of CBD and other phytocannabinoids on extracellular signal-regulated kinase (ERK) cascade in cancer. Although ERK is considered as a rather pro-proliferative signaling molecule, it has been shown that sustained activation of ERK induces apoptosis in astrocytes.

The identified target receptors are presented in figure 1; the signal target molecules and pathways are presented in table 2. As it is shown, CBD has affinity not only to CB receptors, but also to ion type vanilloid receptors, TRPV1, TRPV2 (Bisogno et al. 2000; Iannotti et al. 2014). TRP ion channels are present in the plasma membrane of a variety of cells in many tissues and act as ligand-gated, nonselective cation channels permeable to sodium, calcium, and magnesium ions. As targets for CBD they accounted 15% of the known molecular targets. CBD acts as an agonist at human TRPV1 channel expressed in HEK293 tumor cells, and induces increases in intracellular calcium ([Ca^{2+}]), but the potential role of these effects remains less well defined. The role of ‘orphan’ G protein-coupled receptors GPR55, GPR3, and GPR6 is also unknown (Pyszniak et al. 2016; Laun and Song 2017). The peroxisome proliferator-activated receptor (PPARγ), otherwise known as the glitazone receptor, is thought to be responsible for lipid storage and glucose metabolism, and some anticancer effects of CBD are thought to be mediated through interaction with PPARγ (Kano et al. 2009). PPARγ activation is becoming an important target in lung metastases and colon carcinogenesis. However the exact role of all these receptors in endocannabinoid signaling is still under discussion. Theoretically there is a general consensus that cannabinoids have multiple target molecules and signal pathways which participate in the control of the tumor growth and progression. It is diligent to note that the lipophilic nature of CBD and the membrane-bound nature of many of these targets reflected nonspecific interaction between them. Moreover, CBD acts on tumor growth and tumor progression by target oriented action on the signal molecules and pathways, and in many cases these effects are reached in receptor-independent manner.

**Anticancer activity**

A number of mutations that inhibit apoptosis have been found in tumors. In the first phase of tumor progression the cancer cells become locally invasive; in the second phase the most lethal attribute of cancer cells is their ability to disseminate and colonize secondary sites with metastases. Tumor progression is defined by irreversible changes in the tumor characteristics, reflecting genetically altered subpopulation of cells (Aguirre-Ghiso 2007; Welch and Hurst 2016). Despite these well-recognized facts, the majority of cancer research funding still focuses on primary carcinogenesis. In contrast, the investigations with phytocannabinoids, their synthetic derivatives, and endocannabinoids are oriented predominantly to the possibility to inhibit tumor progression, and are reviewed in Hermanson and Bih et al. (2015) receptor targets of CBD account for only 15% of the known molecular targets. CBD acts as an agonist at human TRPV1 channel expressed in HEK293 tumor cells, and induces increases in intracellular calcium ([Ca^{2+}]), but the potential role of these effects remains less well defined. The role of ‘orphan’ G protein-coupled receptors GPR55, GPR3, and GPR6 is also unknown (Pyszniak et al. 2016; Laun and Song 2017). The peroxisome proliferator-activated receptor (PPARγ), otherwise known as the glitazone receptor, is thought to be responsible for lipid storage and glucose metabolism, and some anticancer effects of CBD are thought to be mediated through interaction with PPARγ (Kano et al. 2009). PPARγ activation is becoming an important target in lung metastases and colon carcinogenesis. However the exact role of all these receptors in endocannabinoid signaling is still under discussion. Theoretically there is a general consensus that cannabinoids have multiple target molecules and signal pathways which participate in the control of the tumor growth and progression. It is diligent to note that the lipophilic nature of CBD and the membrane-bound nature of many of these targets reflected nonspecific interaction between them. Moreover, CBD acts on tumor growth and tumor progression by target oriented action on the signal molecules and pathways, and in many cases these effects are reached in receptor-independent manner.

**Figure 2.** Some of the potential biological targets of Cannabidiol (CBD): cannabinoid receptors CB1, and CB2; ion channel receptors, incl. transient receptor potential vanilloid (TRPV) type 1 and 2; EGF-R, epidermal-growth factor receptor; ‘orphan’ G protein-coupled receptors, GPR55 and GPR3, GPR6; peroxisome proliferator-activated receptor, PPAR; vascular endothelial growth factor, VEGF-R; allosteric modulation and enhanced activity at α1γ glycine receptor; enhanced activity at the 5-HT1a, adenosine and N-acetylcarnosine receptors; inhibiting activity on mu and delta opioid receptors. Note: (+) stimulation; (-) inhibition.

---

**Anticancer activity**

A number of mutations that inhibit apoptosis have been found in tumors. In the first phase of tumor progression the cancer cells become locally invasive; in the second phase the most lethal attribute of cancer cells is their ability to disseminate and colonize secondary sites with metastases. Tumor progression is defined by irreversible changes in the tumor characteristics, reflecting genetically altered subpopulation of cells (Aguirre-Ghiso 2007; Welch and Hurst 2016). Despite these well-recognized facts, the majority of cancer research funding still focuses on primary carcinogenesis. In contrast, the investigations with phytocannabinoids, their synthetic derivatives, and endocannabinoids are oriented predominantly to the possibility to inhibit tumor progression, and are reviewed in Hermanson and
Marnett (2011); Massi et al. (2013), Rocha et al. (2014), Ladin et al. (2016), and Sledziński et al. (2018).

As it is summarized in table 2, CBD have anti-proliferative and tumor-reductive effects in cell lines and tumor-bearing mice. In most of the cases CBD may cause these effects in receptor-independent manner, but the role of two signal pathways (ERK and ROS) is very important. Also, it is well known that the phosphatidylinositol 3 kinase (PI3K) pathway is one of the major pathways modulating cell growth, proliferation, metabolism, survival, and angiogenesis. Hyperactivation of this pathway is one of the most frequent occurrences in human cancer and is thus an obvious target for anticancer treatment.

CBD induces two forms of the programmed cell death: autophagy and intrinsic or mitochondria-mediated apoptosis, as it is shown on breast cancer cells by Shrivastava et al. (2011). Induction and accumulation of de novo synthesis of ceramide lead to an activation of endoplasmic reticulum (ER) stress-related signaling pathway. Interestingly, ROS generation is available in different cell lines after treatment with CBD, and seems to be needed for CBD-induced autophagy and apoptosis. The inhibition of tumor invasion in surrounding tissue after treatment with CBD is associated with the inhibition of Id-1 expression, as it is discovered in brain and breast cancer by McAllister et al. (2007, 2011). Additionally, intracellular adhesion anti-metastatic protein ICAM-1 participates in the realization of CBD anti-metastatic effects in lung cancer, discovered by Ramer et al. (2012).

Moreover, CBD induces endothelial cell cytostasis and inhibits angiogenesis in vivo by receptor-mediated manner (Hermanson and Marnett 2011).

Breast cancer

Breast cancer can be divided into three sub-types: hormone sensitive, HER2-positive, and triple negative breast cancer. CB1 receptors were reported to be present in 28% of all breast carcinoma patients, CB2 receptors were found in 72% of breast carcinomas and 91% of these tumors were HER2 positive. A correlation between CB2 receptor expression and breast cancer aggressiveness has been proposed (Qamri et al. 2009; Caffarel et al. 2010; Caffarel et al. 2012; Pérez-Gómez et al. 2015).

In 2006 for the first time Ligresti et al. (2006) demonstrated CBD’s anti-proliferative effect on MCF7 and MDA-MB-231 breast tumour cell lines (IC50 between 6.0 and 10.6 mmol/L). It was shown that CBD exhibits the most potent antiproliferative action as compared to other cannabinoids. Additionally, CBD and the CBD-rich extract inhibit the growth of xenografts of human MDA-MB-231 cells, and reduce lung metastases. It was shown that CBD’s antitumor effect is due to its capability to induce apoptosis via direct or indirect activation of cannabinoid CB2 and vanilloid receptors, with participation of the ROS (Bifulco et al. 2006). Later data for CBD inhibiting effect was shown on breast cancer progression (McAllister et al. 2007). For the first time in this study the important role of CBD for downregulation of the expression of key genes involved in the control of cell proliferation and invasion as Id-1 protein, of basic helix-loop-helix transcription factor, and regulator of cell growth and tissue-specific differentiation was discovered (Perk et al. 2005). It was found that overexpression of Id-1 in breast cancer cells is responsible for cancer progression. Four years later McAllister et al. (2011) discover that the CBD-induced effects on cell proliferation and Id-1 expression was mediated by the extracellular signal-regulated kinase (ERK) and reactive oxygen species (ROS) pathways. Moreover, these in vitro received data was confirmed in vivo in multiple breast cancer models including; two orthotopic, one genetically engineered mouse model and one TNBC xenograft model (Ligresti et al. 2006; McAllister et al. 2011; Murase et al. 2014; Elbaz et al. 2015). Furthermore, two of these studies which used genetically engineered and xenograft models proposed that CBD elicited these effects by inhibiting EGF-R activation, cytokine secretion, and Akt expression (McAllister et al. 2011; Elbaz et al. 2015). The anti-metastatic effect of CBD was defined in vivo with 4T1 breast cancer cells injected into the tail vein of syngeneic BALB/c mice. It was shown that 1 and 5 mg/kg CBD reduces primary tumor growth and the number of metastatic foci. Although CBD has negligible affinity for CB1 and CB2 receptors, CBD has been shown to control cell migration through the activation of ERK enzyme (Mo et al. 2004).

The excellent experiments provided by Shrivastava et al. (2011) highlighted the potential use of CBD as an anticancer agent. These authors showed that CBD induces a concentration-dependent cell death in two oestrogen receptor-positive and oestrogen receptor-negative breast cancer cells in a receptor-independent manner. They determined CBD-mediated autophagy and apoptosis by inducing endoplasmic reticulum stress in breast cancer cells and inhibiting AKT/mTOR/4EBP1 signaling. It is well known that these pathways are frequently activated in human cancers, and modulate breast cancer metastasis, cancer cell proliferation, and acquired drug resistance (Rosen and She 2006). Additionally, the authors obtained caspase-dependent apoptosis in MDA-MB-231 cells via the mitochondria-mediated signaling pathway. It was demonstrated that CBD-driven increase in ROS production is needed not only for apoptosis, as the impaired mitochondrial function is a result of increased ROS production (Zorov et al 2000), but also is associated with autophagy (Chen and Gibson 2008).

Glioma and Glioblastoma

Glioma is CNS brain tumor subtype from glial tissue and accounts for approximately 80% of all primary malignant brain tumors (Ostrom et al. 2015). These types of tumors are characterized with a high morphological and genetic heterogeneity, high proliferative rate, aggressive invasiveness and insensitivity to radio- and tra-
dritional chemotherapy (Rocha et al. 2014; Dumitru et al. 2018). There is a general consensus that high-grade gliomas, including glioblastoma (GBM), express high levels of CB2 receptors. Furthermore, CB2 expression positively correlates with the malignancy grade (reviewed in Ellert-Miklaszewska et al. 2013). Therefore, therapeutic strategies aimed at inhibiting the migration and invasion of glioma tumor cells are of great clinical relevance in the management of the disease (Velasco et al. 2007; Russo 2018).

There are many investigations with THC and synthetic cannabinoids, including a clinical trial. The pre-clinical results demonstrate specific cytotoxicity of cannabinoids, including CBD, in glioma cell line U87-MG and U373 and subcutaneous animal models through the induction of apoptosis (Massi et al. 2004, 2006). These investigators evaluate the anti-proliferative effect of CBD as cannabinoid- and vanilloid- receptors independent. It was shown that apoptotic cell death in glioma cells is due to the induction of de novo synthesis of ceramide with proapoptotic activity (reviewed in Śledziński et al. 2018). Most importantly, for the first time antitumor activity of CBD in glioma cells was associated with oxidative stress: increasing of ROS production, depletion of intracellular glutathione and increased GSH-associated enzyme activity (Massi et al. 2010; Singer et al. 2015). But CBD did not induce ROS production in non-transformed primary glial cells. The inhibitory effect of CBD in multiple GBM cell lines was confirmed by Marcu et al. (2010), and in animals orthotopically implanted with primary 3832 and 387 glioblastoma cells (Soroceanu et al. 2013). The mechanism of anti-proliferative effect of CBD is defined as inhibition of the Ras/Raf/MEK/ERK pathway in human glioblastomas. The other investigators (Solinas et al. 2012, 2013) show the anti-invasive effect of CBD on GBM even at low concentrations, which are not sufficient to induce cell death. This effect of CBD was attributed to the inhibition of Id-1 expression and Sox-2 protein. Several studies have shown that CBD and some other cannabinoids are capable to inhibit tumor neoangiogenesis on animal models and in patients with recurrent GBM (Blázquez et al. 2003, 2004; Blázquez et al. 2008a, 2008b; Solinas et al. 2012). Anti-angiogenic activity of CBD corresponds to downregulation of pro-angiogenic factors such as MMP2 and MMP9, endothelin-1 (ET-1), platelet-derived growth factor-AA (PDGF-AA) and some chemokines. In addition, CBD inhibits the hypoxia-inducible transcription factor HIF-1α, one of the most critical stimuli for cell survival, motility and tumour angiogenesis. Despite of these studies the role of cannabinoids and CBD in glial tumor cells migration and invasion is still poorly characterized.

**Colon cancer**

It was established that there is a positive correlation between CB2 receptor expression and human colon cancer growth. So, the expression of CB2 receptor is a poor prognostic marker in advanced stages of colon cancer (Martinez-Martinez et al. 2015). *In vitro* studies support the beneficial effect of CBD in colorectal carcinoma cell lines: CBD protects DNA from oxidative damage, increased endocannabinoid concentrations and reduced tumor-cell proliferation. In chemically-induced azoxymethane colon carcinogenesis, CBD and *Cannabis sativa* extract (which contains high CBD content) reduced aberrant crypt foci formation and the number of precancerous polyps and tumors (Aviello et al. 2012; Romano et al. 2014). *In vitro* experiments suggested that the cytotoxicity was mediated by CB1, TRPV1, and PPARy or CB2 receptors. The researchers propose that the effects of CBD are associated with the upregulation of phospho-Akt, iNOS and COX-2 and the downregulation of caspase-3. Cianchi et al. (2008) define the increase of ceramide production and apoptosis through tumor necrosis factor alpha. These results suggest that CBD might be worthy of clinical consideration in colon cancer prevention.
Pancreatic cancer

Pancreatic cancer is a type of cancer that has some of the lowest survival rates because there are very few, and mostly only palliative care, treatments available. It was discovered that the ECS plays an active role in pancreatic carcinogenesis. It was obtained that CB1 and CB2 receptor expression was elevated in human pancreatic tumors when compared to normal pancreas. Although the levels of endocannabinoids (AEA, 1-AG, 2-AG) were unchanged in pancreatic cancer compared to normal human pancreas, high levels of CB1 receptor expression and low levels of endocannabinoid degrading enzymes (FAAH and MAGL), are associated with shorter survival (Carracedo et al. 2006). The provided experiments of this scientific group showed that cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Recently, prof. Marco Falasca and colleagues have conducted a study on mice that had been genetically modified to develop pancreatic cancer. This study shows that a gene known as GPR55 is involved in the growth and multiplication of pancreatic cancer cells. This gene gives rise to proteins that sit in cell membranes and detect various substances, including cannabis-derived molecules. Most importantly, it was obtained that CBD hinders the development of resistance to gemcitabine, as it is shown below. This result is associated with the blocking action of CBD on the receptors produced by the GPR55 gene, preventing them from interaction with endogenic molecules which promote the cell proliferation and tumor growth (Ferro et al. 2018).

Prostate cancer

The available three common primary therapies for prostate cancer (chirurgical, radiotherapy and brachytherapy) showed a unique pattern of changes in quality of life related to urinary symptoms, sexual and bowel function, and vitality or hormonal function of patients. It was obtained for the first time that the levels of CB1 and CB2 receptor was elevated in prostate cancer compared to normal prostate tissue (Sarfaraz et al. 2005), and it is associated with poor disease outcome. In vitro experiments of de Petrocellis et al. (2013) on four prostate cell lines (PC-3, DU-145, 22RV1, and LNCaP) show that CBD decreased androgen receptor expression and may affect tumor growth. Additionally, CBD significantly increased the generation of ROS and pro-apoptotic CHOP10 expression in these prostate cancer cell lines. In vivo study obtained that CBD effectively decreased tumor growth in androgen-sensitive, PSA-positive LNCaP cells xenografts, but potentiated tumor growth of androgen receptor negative DU-145 xenografts. Additionally, other investigations with endocannabinoids (Sánchez et al. 2003a, 2003b; Olea-Herrero et al. 2009) try to obtain the relationship between ECS, androgen receptor signaling and cannabinooid efficacy but currently the mechanism of action is not yet understood. Limited data makes it impossible to evaluate the potential application of CBD for the management of prostate cancer as it is proposed by Sarfaraz et al. (2005).

Leukaemia/Lymphoma

The study of McKallip scientific group (2002) demonstrated that ligand of CB2 receptors can induce apoptosis in a wide range of cancers of immune-cell origin. After that Gallily et al. (2003) provided the first evidence of a possible use of CBD in the treatment of lymphoblastic diseases. They demonstrated that CBD treatment induces apoptosis, through caspase-3 activation in human acute myeloid leukaemia HL-60 cell line, whereas it had no effect on normal human monocytes. Later on, McKallip et al. (2006) in experiments with the murine EL-4 lymphoma cell line, the human Jurkat and Molt-4 leukaemia cell lines, demonstrate that CBD induce CB2 receptor-mediated decrease in the number of viable cells as well as the induction of apoptosis, both in vitro and in vivo. In Jurkat cells, exposure to CBD resulted in the activation of caspase-8, -9, and -3, the cleavage of poly (ADP-ribose) polymerase and the decrease in full-length of Beclin2 interaction protein (Bid). These data suggest a possible cross-talk between the intrinsic and extrinsic apoptotic pathways. Moreover, exposure to CBD led to the loss of mitochondrial membrane potential and subsequent release of cytochrome C. As in other tumour cells, CBD-induced apoptosis required an increase of ROS production. Finally, CBD decreased the levels of phospho-p38 mitogen-activated protein kinase (McKallip et al. 2006), and this effect was blocked by treatment with a CB2-selective antagonist or ROS scavenger as tocopherol. Briefly, the received results suggest that CBD, acting through CB2 receptors and ROS production, may represent a novel and highly selective treatment for lymphoblastic diseases.

Multiple myeloma

Multiple myeloma (MM) is a haematological B cell malignancy characterised by clonal proliferation of plasma cells and their accumulation in the bone marrow (Rajkumar 2011). MM cells exhibit mutations in the nuclear factor kappalight-chain-enhancer of activated B cells [NF-jB] pathway, and this family of transcription factors involved in the regulating of the MM proliferation, survival and chemoresistance. TRPV2 gene mutations (gain or loss of function) have been identified in haematological disorders such as MM (Fabris et al. 2007; Santoni et al. 2011, 2013). The excellent investigations of Morelli et al. (2014) show for the first time that CBD induces cytotoxicity in MM cells and this effect was amplified in TRPV2-positive cells. CBD inhibits proliferation of TRPV2-transfected cells and increased the percentage of cells in the sub-G1 and G1 phases compared with untransfected cells. They found that the effect of CBD on TRPV2-transfected MM cells was independent of the CB1 and CB2
receptors, TRP ion receptors and PPARy. The researchers demonstrate also that CBD and proteasome inhibitor drug bortezomib alone inhibit ERK activation in TRPV2-transfected and untransfected MM cells, albeit at lower levels. In addition, CBD and bortezomib strongly abrogated Akt phosphorylation (approximately 80% inhibition in TRPV2-transfected MM cells). Finally, the investigated compounds induce mitochondrial and ROS-dependent necrosis in MM cell lines.

**Combination and adjuvant therapy**

Many *in vitro* and *in vivo* studies have shown the anticancer activity of CBD, with reports advocating for investigations of combination therapy approaches that could better leverage these effects in clinical translation. In fact, the administration of CBD together with some anticancer drugs has been shown to increase the susceptibility of glioblastoma cells to the cytotoxic effects of drugs (Nabissi et al. 2013). The studies of Morelli et al. (2014) demonstrate that CBD and bortezomib (using the lowest effective dose for each component) synergistically reduced the viability of TRPV2-transfected and untransfected MM cell lines (CI<1). The authors found that cannabinoid, applied alone or simultaneously with bortezomib, kills multiple myeloma cells, particularly when TRPV2 was expressed. In addition, the growth of CD34+ cells isolated from healthy blood donors is unaffected by this combination. Triggering of the TRPV2 ion channel by cannabinoid sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents (Nabissi et al. 2013). These data suggest that treatment with CBD may help sidestep the problem of patients developing resistance to bortezomib.

The scientific group of prof. M. Falaska demonstrated some striking experimental evidence regarding CBD and combination chemotherapy. Mice with pancreatic cancer survived nearly three times longer when their cytostatic treatment was combined with the cannabis-derived compound. Gemcitabine and synthetic cannabinoids combinations trigger autophagy in pancreatic cancer cells through a ROS-mediated mechanism (Donadelli et al. 2011). These data highlighted the possibility for simultaneously application of CBD and gemcitabine, both currently approved for medicinal use in the UK and USA, in patients with pancreatic cancer as novel promising treatment. Strong et al. (2018) evaluate in vitro the anti-proliferative effect of CBD and some new inhibitors used for treatment of two aggressive forms of Non-Hodgkin lymphoma. Synergistic potential of CBD with Bruton’s tyrosine kinase inhibitors such as ibrutinib and proteasome inhibitors such as carfilzomib is observed. Data shows a marked reduction in viability of DLBCL and MCL cell lines after combination treatment. The exposure to CBD and ibrutinib lowered the cell viability to under 25% as compared to control whereas, individually the drugs never fall under 75% of control.

Synergistic pharmacological effects are observed also for cannabinoids and paclitaxel in gastric cancer cell lines (Miyato et al. 2009); cannabinoids and temozolomide against glioma cell lines (Torres et al. 2011). The studies of Aviello et al. (2012) show that CBD in combination with paclitaxel produces additive to synergistic inhibition of colon cancer cell viability. Our investigations with CBD and epirubicin show that combination treatment of sensitive and resistant myeloid HL-60 cell lines has advantages in relation to the anti-proliferative effect reached in smaller concentration. Additionally, we observe pro-oxidant and antioxidant effects of epirubicin and CBD in dependence of applied concentration (Zhelyazkova et al. 2019; and unpublished data). These results confirm the hypothesis that CBD could enhance positively the activity of first-line antitumor drugs.

Available pre-clinical data for combination treatment with CBD and cytostatic agents are very limited. Additionally, the experiments are provided with different methodical approaches and there is a difficulty to make a comparative analysis. There is an urgent need to apply standard procedure for quantitative assay of the combination treatment as recommended by Chou TC (2007). But, it is clear, that combination therapy utilizing non-psychoactive cannabinoid CBD and conventional treatment may be a beneficial option for patients with advanced or resistant cancer.

Another direction for using cannabinoids is as adjunctive drugs. The aim of this treatment is to prevent or reduce cytostatic-induced side-effects. In particular, THC (Marinol), its analog nabilone (Cesamet), and buccal spray Sativex (Nabiximol, containing THC and CBD 1:1) were brought onto the market in several countries owing to their ability to inhibit chemo- and radiotherapy-induced side effects (Chakravarti et al. 2014), despite of the fact that it is not recommended by NICE (UK Medicines Information 2018). Sativex is approved for muscle spasticity in patients with multiple sclerosis but is used for neurological pain in cancer patients. Cesamet is indicated for prevention of chemotherapy-induced emesis.

The most terrible unwanted effect of some cytostatic drugs, including taxanes, platinum agents and Vinca alkaloids is drug-induced peripheral neuropathy. This side effect occurs in 30–40% of patients but incidences can reach 75% with certain regimens of chemotherapy. The pre-clinical investigations of Ward et al. (2014) show that CBD in doses 2.5 and 5 mg·kg⁻¹, administered only before each of the four paclitaxel injections of a standard dosing regimen for inducing neuropathy pain in rodents, prevents the development of paclitaxel-induced mechanical sensitivity in female C57Bl/6 mice. This effect is in part mediated by the serotonin 5-HT₄ receptors as it proposed by Russo et al. (2005). Another investigation shows that CBD attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress (Pan et al. 2009). These results indicate that CBD is a potent adjuvant to chemotherapy for the purposes of patient comfort, ultimately improving
Table 2. Effects of cannabidiol on different types of cancer cells*.

| Effects               | Target receptors | Autophagy / apoptosis | ROS | Cell signaling pathway and target signal molecules |
|-----------------------|------------------|-----------------------|-----|---------------------------------------------------|
| Breast cancer         |                  |                       |     | ▪ pro-survival pathways                           |
| ▪ proliferation       | TRPV1, EGF-R     | NC                    | +   | ↑ P38/Akt** and                                    |
| ▪ viability           | CB2, R           | +                     |     | ↑ Raf1/MEK/ERK                                     |
| ▪ invasion*           | non-CB1, non-TRPV1 | NC                   | NC  | ↑ EGFR, Id-1, T cytochrome C, Bid translocation.  |
| Glioma, Glioblastoma  |                  |                       |     | ▪ Ras/Raf/MEK/ERK                                 |
| ▪ proliferation       | non-CB1, non-TRPV1| NC                    | +   | ↑ (p-ERK, p-Akt); Capase activity, ↓ ceramide     |
| ▪ invasiveness*       | CB2, TRPV2       | NC                    | NC  | ↓ HIF-1a, MMP-2, -9; ↓ Id-1, ↓ Sox-2 (protein)    |
| ▪ migration*          |                  |                       |     | ↑ VEGF and other factors                           |
| ▪ angiogenesis*       | VEGF-R           | NC                    | NC  | ↑ ICAM-1; ↑ TIMP-1 (protein)                      |
| Lung cancer           |                  |                       |     | ▪ PPARγ and COX-2                                 |
| ▪ proliferation       | CB-R, TRPV1      | +                     |     | ↑ p-p38, p-ERK                                    |
| ▪ invasiveness*       |                  |                       |     | ↑ caspase-3 activity, COX-2                       |
| ▪ metastasis*         | PPARγ            | NC                    | NC  | ↑ ceramide, ↓ Akt, ↓ 2-AG, TNFα-mediated apoptosis. |
| Colon cancer          |                  |                       |     | ▪ ER-stress-related genes                         |
| ▪ proliferation       | CB1/CB2, TRPV1, PPARγ | NC             | +   | ↓ ECS pathway                                    |
| ▪ Chemoprevention     |                  |                       |     | ↓ enzymes (FAAH, MAGL)                           |
| ▪ or ↑ proliferation  | CB1, CB2, other receptors | (with other cannabinoids) | + | ↑ CHOP10 (protein)                               |
| Prostate cancer       |                  |                       |     | ▪ caspase-3, -8, -9 activation                    |
| ▪ proliferation       | GPR55, CB1, CB2 | NC                    |    | ↑ p-38 MAPK                                       |
| ▪ or chemotherapy      |                  |                       |     | ↑ Bid translocation                               |
| Leukaemia/Lymphoma    |                  |                       |     | ↑ cytochrome C                                    |
| ▪ viability,          | CB2              | NC                    | +   | ↑ p-Akt                                            |
| ▪ cytoreduction       |                  |                       |     | Cell cycle arrest in G1                           |
| Multiple myeloma      |                  |                       |     | ▪ ERK activity                                    |
| ▪ proliferation       | TRPV2            | Mitochondrial and ROS-mediated necrosis | + | ↑ p-Akt                                            |

* Study on orthotopic and subcutaneous animal models; other data are received in vitro; 2-AG, 2-arachidonoyl glycerol; Bid, Beclin2 interaction protein; CB, EGF-R; TRPV, PPARγ, VEGF-R, as in fig 1; ERK, extracellular regulated kinase; ER, endoplasmic reticulum; FAAH, fatty acid amide hydrolase; HIF-1α, hypoxia-inducible transcription factor; ICAM, intra-cellular adhesion anti-metastatic (protein); MAPK, mitogen-activated protein kinase; MAGL, monoacyl glycerol lipase; MMP, matrix metalloproteinase; ROS, radical oxygen species; TIMP, tissue inhibitor of MMPs; VEGF, vascular endothelial growth factor. Note: NC = not checked; ↑ increase; ↓ decrease.

In conclusion

The available scientific pre-clinical data show that CBD may be applied in cancer therapy. Its low toxicity and non-psychoactive profile of action are a good starting point for clinical trial and suggest possible exploitation for prolonged treatment. CBD has anticancer activity in different type malignant tumors and more interesting this cannabinoid has influence on tumor progression. Significantly important are data for its synergistic anticancer activity with other cytostatic drugs, its tumor-sensitizing or protective effects which create a possibility for application of CBD as a component of combination schedule of chemotherapy or as adjunctive drug.

In the light of its safety record and considering that CBD is currently used in clinical practice, the findings here summarized suggest that CBD might be worthy of clinical consideration for cancer therapy. It may be proposed that cannabinoid effectiveness of CBD is directed against the changes in the tumor cells received in the different stages of cancerogenesis, reducing the expression of the Id-1 gene, and some other signal molecules that are over-expressed in aggressive forms of cancer (Alberts et al. 2002; Ladin et al. 2016). Though some important achievements have been made in our understanding for cannabinoids, their immunosuppressive effect and relation between ECS and other cell signal pathways are still unknown. The information for interactions of CBD with clinically applied anticancer drugs must be well identified on pre-clinical and clinical levels. But the route of administration appears more problematic since CBD oral absorption is slow and unpredictable. The available studies and observed problems lead us to the conclusion, that further profound studies in some directions are doubtlessly needed to verify the rational idea of introducing cannabidiol into the cancer chemotherapy.
References

Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer 7(11): 834–846. https://doi.org/10.1038/nrc2256

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) The Molecular Basis of Cancer-Cell Behavior. New York: Garland Science, 1616 pp.

Arellano AL, Papaseit E, Romaguera A, Torrens M, Farre M (2017) Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. CNS Neurol Disord Drug Targets 16(5): 554–566. https://doi.org/10.2174/18715273201617041304516

Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, Di Marzo V, Izzo AA (2012) Chemopreventive effect of the non-psychoactive phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine (Berlin, Germany) 90(8): 925–934. https://doi.org/10.1007/s00109-011-1085-x

Batalla A, Crippa JA, Busatto GF, Guimarães FS, Zuardi AW, Valverde O, Atakan Z, McGuire PK, Bhattacharyya S, Martín-Santos R (2014) Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Current pharmaceutical design 20(13): 2168–2185. https://doi.org/10.2174/18715273186313199990432

Bergamaschi MM, Queiroz RH, Zuardi AW, Criippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety 6(4): 237–249. https://doi.org/10.2174/1574868111798280924

Bifulco M, Laezza C, Pisanti S, Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 148: 123–135. https://doi.org/10.1038/sj.bjp.0706632

Bih CI, Chen T, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12: 699–730. https://doi.org/10.1007/s13311-015-0377-3

Bisogni T, Hanui L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134(4): 845–852. https://doi.org/10.1038/sj.bjp.0704327

Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G, Malumbres M, Guzmán M (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. The FASEB Journal 20(14): 2633–2645. https://doi.org/10.1096/fj.06-6387fj

Blázquez C, Carracedo A, Salazar M, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M (2008a) Down-regulation of tissue inhibitor of metalloproteinase-1 in gliomas: a new marker of cannabinoid antitumour activity? Neuropharmacology 54: 235–243. https://doi.org/10.1016/j.neuropharm.2007.06.021

Blázquez C, Casanova ML, Planas A, Gómez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal 17(3): 529–531. https://doi.org/10.1096/fj.02-0795fj

Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research 64: 5617–5623. https://doi.org/10.1158/0008-5472.CAN-03-3927

Blázquez C, Salazar M, Carracedo A, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M (2008b) Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Research 68: 1945–1952. https://doi.org/10.1158/0008-5472.CAN-07-5176

Caffarel MM, Andrades C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C (2010) Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer 9: 196–206. https://doi.org/10.1186/1476-4598-9-196

Caffarel MM, Andrades C, Pérez-Gómez E, Guzmán M, Sánchez C (2012) Cannabinoids: a new hope for breast cancer therapy? Cancer Treatment Reviews 38(7): 911–918. https://doi.org/10.1016/j.ctrv.2012.06.005

Carracedo A, Gironella M, Lorente M, García S, Guzmán M, Velasco G, Iovarina JL (2006) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Research 66: 6748–6755. https://doi.org/10.1158/0008-5472.CAN-06-0169

Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M (2003) Inhibition of skin tumour growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation 111(1): 43–50. https://doi.org/10.1172/JCI20031616

Chakravarti B, Ravi J, Ganju RK (2014) Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 5(15): 5852–5872. https://doi.org/10.18632/oncotarget.2233

Chen Y, Gibson SB (2008) Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy 4: 246–248. https://doi.org/10.1016/j.auto.2004.10.002

Chetty M, Miller R, Moodley SV (1994) Smoking and body weight influence the clearance of chlorpromazine. European Journal of Clinical Pharmacology 46(5): 523–526. https://doi.org/10.1007/BF00196109

Chou TC (2007) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 59: 1–124.

Ciachni F, Papucci L, Schiavone N, Luli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, Donnini M, Perigil G, Trailori G, Tanganelli E, Capaccioli S, Masini E (2008) Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clinical Cancer Research 14(23): 7691–7700. https://doi.org/10.1158/1078-0432.CCR-07-5176

Donadelli M, Dando I, Zaniboni T, Costanzo C, Pozza ED, Scupoli T, Scarpa CG, Cristino I, Orlando P, Di Marzo V (2013) Non-THC cannabinoids counteract prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. British Journal of Pharmacology 168: 79–102. https://doi.org/10.1111/j.1476-5381.2012.02027.x

del Pulgar TG, Velasco G, Sánchez C, Haro A, Guzmán M (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal 363(1): 183–188. https://doi.org/10.1042/bj03630183

Dumitru CA, Sandaicighiou IE, Karsak M (2018) Cannabinoids in glioblastoma therapy: new applications for old drugs. Frontiers in Molecular Neuroscience 11: 1–159. https://doi.org/10.3389/fnmol.2018.00159

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahuirwar DK, Xiao H, Oghamnu S, Satoskar AR, Shilo K, Carson WE, Ganju RK (2015) Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel
anti-tumor mechanisms of cannabinoid in breast cancer. Molecular Oncology 9(4): 906–919. https://doi.org/10.1016/j.molonc.2014.12.010
Ellert-Miklaszewska A, Ciechomska I, Kamińska B (2013) Cannabinoid signaling in glioma cells. Advances in Experimental Medicine and Biology 896: 209–220. https://doi.org/10.1007/978-94-007-4719-7_11
Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, Guerrieri S, Lambertenghi-Dellilie G, Berton E, Neri A (2007) Molecular and transcriptional characterization of the novel p11.2-p12 amphicon in multiple myeloma. Genes Chromosomes and Cancer 46: 1109–1118. https://doi.org/10.1002/gcc.20494
Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, Guerrieri S, Lambertenghi-Dellilie G, Berton E, Neri A (2007) Molecular and transcriptional characterization of the novel p11.2-p12 amphicon in multiple myeloma. Genes Chromosomes and Cancer 46: 1109–1118. https://doi.org/10.1002/gcc.20494
Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M (2018) GPR35 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 37: 6368–6382. https://doi.org/10.1038/s41388-018-0393-0
Gallily R, Even-Chena T, Katzavian G, Lehmann D, Dagan A, Mechoulam R (2003) Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychoactive cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leukemia and Lymphoma 44(10): 1767–1773. https://doi.org/10.1080/1042819031000103917
Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Formukong EA, Evans AT, Evans FJ (1989) The inhibitory effects of canabidivarin (CBD), a non-psychotropic cannabinoid, on human platelet aggregation. Journal of Pharmacy and Pharmacology 41(10): 705–709. https://doi.org/10.1111/j.1369-1600.2012.00483.x
Freimuth N, Ramer R, Hinz B (2010) Antitumorigenic effects of cannabinoids beyond apoptosis. The Journal of Pharmacological and Experimental Therapeutics 332(2): 336–344. https://doi.org/10.1124/jpet.109.157735
Gastonguay EA, Evans AT, Evans FJ (1989) The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. Journal of Pharmacy and Pharmacology 41(10): 705–709. https://doi.org/10.1111/j.1369-1600.2012.00483.x
González-Díaz CA, Soliman LT, Griffin LT, Vakharia VY, Anderson J, Pertwee RG (2014) Non-psychoactive plant cannabinoids, cannabidiolin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chemical Neuroscience 5: 1131–1141. https://doi.org/10.1021/nn500524
Ifland K, Grotenhermen F (2017) An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research 2(1): 139–154. https://doi.org/10.1089/can.2016.0034
Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009) Non-psychoactive plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences 30(10): 515–527. https://doi.org/10.1016/j.tips.2009.07.006
Jiang R, Yamaori S, Takeda S, Yamamoto M, Watanabe K (2011) Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences 89(5–6): 165–170. https://doi.org/10.1016/j.lfs.2011.05.018
Kano M, Ohno-Shosaku T, Hashimoto Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews 89: 309–380. https://doi.org/10.1152/physrev.00019.2008
Kaplan BL, Springs AE, Kaminski NE (2008) The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochemical Pharmacology 76(6): 726–737. https://doi.org/10.1016/j.bcp.2008.06.022
Katsidoni V, Anagnostou I, Panagis G (2013) Cannabidiol inhibits the reward facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addiction Biology 18(2): 286–296. https://doi.org/10.1111/j.1369-1602.2012.00483.x
Keshamouni VG, Reddy RC, Aremberg DA, Joel B, Thannickal VJ, Kalederian GP (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 1–1000. https://doi.org/10.1038/sj.onc.1206885
Ladin DA, Soliman E, Griffin LJ, Van Dross R (2016) Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Frontiers of Pharmacology 7: 1–361. https://doi.org/10.3389/fphar.2016.00361
Laun AS, Song ZH (2017) GPR3 and GPR6, novel molecular targets for cannabinoids. Biochemical and Biophysical Research Communications 490: 17–21. https://doi.org/10.1016/j.bbrc.2017.05.165
Ligresti A, Moriello AS, Starowicz K, Matias I, Piantelli M, Portella C, Portella G, Bifulco M, Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. The Journal of Pharmacology and Experimental Therapeutics 318(3): 1375–1387. https://doi.org/10.1124/pet.106.105247
Long LE, Chesworth R, Huang X, McGregor I, Arnold J, Karl T (2010) A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6J mice. International Journal of Neuropsychopharmacology 13(7): 861–876. https://doi.org/10.1017/S1461145709990605
Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, Keshamouni VG, Reddy RC, Aremberg DA, Joel B, Thannickal VJ, Kalederian GP (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 1–1000. https://doi.org/10.1038/sj.onc.1206885
Ligresti A, Moriello AS, Starowicz K, Matias I, Piantelli M, Portella C, Portella G, Bifulco M, Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. The Journal of Pharmacology and Experimental Therapeutics 318(3): 1375–1387. https://doi.org/10.1124/pet.106.105247
Long LE, Chesworth R, Huang X, McGregor I, Arnold J, Karl T (2010) A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6J mice. International Journal of Neuropsychopharmacology 13(7): 861–876. https://doi.org/10.1017/S1461145709990605
Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, Pakdel A, Allison J, Limbad C, Moore DH, Yount GL, Desprez PY, McCaillister SD (2010) Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular Cancer Therapeutics 9: 180–189. https://doi.org/10.1158/1535-7163.MCT-09-0407
Marks MD, Tian L, Weng J P, Omburo SN, Soto-Fuentes W, He J, Gang DR, Weihlen GD, Dixon RA (2009) Identification of candidate genes affecting Δ9- tetrahydrocannabinol biosynthesis in Cannabis sativa. Journal of Experimental Botany 60(13): 3715–3726. https://doi.org/10.1093/jxb/erp210

Martínez-Martínez E, Gómez I, Martín P, Sánchez A, Román L, Tejerina E, Bonilla F, Merino AG, de Herreros AG, Provencio M, García JM (2015) Cannabinoids receptor type 2, CR2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience 2(2): 131–141. https://doi.org/10.18632/oncoscience.119

Massi P, Solinas M, Cinquina V, Parolaro D (2013) Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology 75(2): 303–312. https://doi.org/10.1111/bjc.12125.2012.04298.x

Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D (2006) The non-psychotoxic cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cellular and Molecular Life Sciences: 63: 2057–2066. https://doi.org/10.1007/s00018-006-6156-x

Massi P, Vaccani A, Ceruti S, Colombo A, Abbraccio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychotoxic cannabinoid, on human glioma cell lines. Journal of Pharmacology and Experimental Therapeutics 308: 838–845. https://doi.org/10.1124/jpet.103.061002

Massi P, Valenti M, Solinas M, Parolaro D (2010) Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers 2: 1013–1026. https://doi.org/10.3390/cancers2021013

McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 6(11): 2921–2927. https://doi.org/10.1158/1535-7163.MCT-07-0371

McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez P (2011) Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research Treatment 129(1): 37–47. https://doi.org/10.1007/s10549-010-1177-4

McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006) Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Molecular Pharmacology 70: 897–908. https://doi.org/10.1124/mol.106.029397

McKallip RJ, Lombard C, Fisher M, Martin BR, Ruy S, Grant S, Nagarkatti PS, Nagarkatti M (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100: 627–634. https://doi.org/10.1182/blood-2002-01-0098

McPartland JM, Duncan M, Vincenzo DM, Pertwee RG (2015) Are cannabinoid and Δ9-tetrahydrocannabinolvarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology 172(3): 737–753. https://doi.org/10.1111/bph.12944

Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chemistry and Physics of Lipids 121(1–2): 35–43. https://doi.org/10.1016/S0009-2745(02)00599-X

Miyato H, Kitayama J, Yamashita H, Souma D, Asakage M, Yamada J, Nagawa H (2009) Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. The Journal of Surgical Research 155(1): 40–47. https://doi.org/10.1016/j.jss.2008.08.045

Mo FM, Offeralter L, Kunos G (2004) Atypical cannabinoid stimulants endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. European Journal of Pharmacology 489(1–2): 21–27. https://doi.org/10.1016/j.ejphar.2004.02.034

Morelli MB, Offidani M, Alesi F, DiScipoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabisii M (2014) The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. International Journal of Cancer 134: 2534–2546. https://doi.org/10.1002/ijc.28591

Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. Journal of the National Cancer Institute 55(3): 597–602. https://doi.org/10.1093/jnci/55.3.597

Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martínez-Martínez E, Amere M, Gujjar R, Mahadevan A, Desprez PY, McAllister SD (2014) Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. British Journal of Pharmacology 171(19): 4464–4477. https://doi.org/10.1111/bph.12803

Nabissi M, Morelli MB, Santoni M, Santoni G (2013) Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34: 48–57. https://doi.org/10.1093/carcin/bgs328

Oesch S, Gertsch J (2009) Cannabinoid receptor ligands as potential anti-cancer agents – high hopes for new therapies? Journal of Pharmacy and Pharmacology 61(7): 839–853. https://doi.org/10.1111/j.1368-8013.2009.02802.x

Olea–Herrero N, Vara D, Malagarie-Cazenave S, Diaz–Laviada I (2009) Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)–Methanandamide and JWH-015: involvement of CB2. British Journal of Cancer 109: 940–950. https://doi.org/10.1038/sj.bjc.6605248

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolsinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncology 17(4): 1–62. https://doi.org/10.1093/neuonc/nov189

Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, Hasko G, Pacher P (2009) Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. The Journal of Pharmacology and Experimental Therapeutics 328(3): 708–714. https://doi.org/10.1124/jpet.108.147181

Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, Garcia-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martin-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Böyum A, Staehler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, Mcl PJ, Cormick G, Guzmán M, Sánchez C (2015) Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. Journal of the National Cancer Institute 107(6): djv077. https://doi.org/10.1093/jnci/djv077

Perk J, Lavrone A, Benezra R (2005) Id family of helix-loop-helix proteins in cancer. Nature Reviews Cancer 5(8): 603–614. https://doi.org/10.1038/nrc1673

Pertwee R (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology 153(2): 199–215. https://doi.org/10.1038/sj.bjp.0707442

Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, JE Groopman, RK Ganju (2011) Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prevention Research 4: 65–75. https://doi.org/10.1158/1940-6207.CAPR-10-0181
Pyszniak M, Tabarkiewicz J, Luszczyk JJ (2016) Endocannabinoid system as a regulator of tumor cell malignancy – biological pathways and clinical significance. OncoTargets and Therapy 18(9): 4323–4336. https://doi.org/10.2147/OTT.S69944

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK (2009) Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Molecular Cancer Therapeutics 8(11): 3117–3129. https://doi.org/10.1158/1535-7163.MCT-09-0448

Rajkumar SV (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86: 57–65. https://doi.org/10.1002/ajh.21913

Ramer R, Blublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, Borchert R, Rohde A, Merkord J, Rohde H, Hinz B (2010) Decrease of glucose metabolism in primary astrocytes. Molecular Pharmacology 79(7): 955–966. https://doi.org/10.1016/j.molpha.2009.11.007

Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Müller R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, Borchert R, Rohde A, Merkord J, Rohde H, Hinz B (2010) Cannabidiol inhibits cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB Journal 24(4): 1535–1548. https://doi.org/10.1096/fj.09-189184

Ramer R, Merkord J, Rohde H, Hinz B (2010) Inhibition of colon carcinogenesis by a standardized Cannabis sativa L. extract in vivo. Frontiers in Integrative Neuroscience 12: 1–51. https://doi.org/10.3389/fnint.2018.00051

Sánchez MG, Ruiz-Llorente L, Sánchez AM, Díaz-Laviada I (2003a) Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15: 851–859. https://doi.org/10.1016/S0898-6568(03)00036-6

Sánchez MG, Sánchez AM, Ruiz-Llorente L, Díaz-Laviada I (2003b) Enhancement of androgen receptor expression induced by (R)-methylamandamide in prostate LNCaP cells. FEBS Letters 555(3): 561–566. https://doi.org/10.1016/S0014-5793(03)01349-8

Santoni G, Farfariello V, Amantini C (2011) TRPV channels in tumor growth and progression. Advances in Experimental Medicine and Biology 704: 947–967. https://doi.org/10.1007/978-94-007-0265-3_49

Santoni G, Farfariello V, Liberati S, Morelli MB, Nabhissi M, Santoni M, Amantini C (2013) The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. Frontiers in Immunology 4: 1–34. https://doi.org/10.3389/fimmu.2013.00034

Sarfaraz S, Afaf I, Adhami VM, Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research 65(5): 1635–1641. https://doi.org/10.1158/0008-5472.CAN-04-3410

Shrivastava A, Kuzomtsoki PM, Groopman JE, Prasad A (2011) Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy. Molecular Cancer Therapeutics 10(7): 1161–1172. https://doi.org/10.1158/1535-7163.MCT-10-1100

Singer E, Judkins J, Salomoni N, Matlaf I, Santon G, Mccallister S, Soroceanu L (2015) Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death and Disease 6: e1601. https://doi.org/10.1038/cddis.2014.566

Slezinski P, Zeyland J, Slomski R, Nowak A (2018) The current state and future perspectives of cannabinoids in cancer biology. Cancer Medicine 7(3): 765–775. https://doi.org/10.1002/cam4.1312

Solinas M, Massi P, Cangelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Benloucif M, Vicentini LM, Noonan DM, Albinini A, Parolari D (2012) Cannabidiol inhibits angiogenesis by multiple mechanisms. British Journal of Pharmacology 167(6): 1218–1231. https://doi.org/10.1111/j.1476-5381.2012.02050.x

Solinas M, Massi P, Cingiu V, Benloucif M, Albinini A, Parolari D (2013) Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS ONE 8(10): e76918. https://doi.org/10.1371/journal.pone.0076918

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, Mcallister S, Solinas M, Massi P, Cingiu V, Benloucif M, Albinini A, Parolari D (2012) Cannabidiol inhibits angiogenesis by multiple mechanisms. British Journal of Pharmacology 167(6): 1218–1231. https://doi.org/10.1111/j.1476-5381.2012.02050.x

Sottrum SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metabolism Reviews 46(1): 86–95. https://doi.org/10.1016/j.drugmetrev.2013.849268
Zhelyazkova M et al.: The pharmacological basis for application of cannabidiol in cancer chemotherapy

252

Straiker A, Dvorakova M, Zimmnowitch A, Mackie K (2018) Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Molecular Pharmacology 94(1): 743–748. https://doi.org/10.1124/mol.118.1111864

Strong T, Rauvolfova J, Jackson E, Pham LV, Bryant J (2018) Synergistic Effect of Cannabidiol with Conventional Chemotherapy Treatment. Blood 132: 1–5382. https://doi.org/10.1182/blood-2018-99-116749

Sultan S, Millar S, England T, O’ Sullivan S (2017) A systematic review and meta-analysis of the haemodynamic effects of Cannabidiol. Frontiers in Pharmacology 8: 1–81. https://doi.org/10.3389/fphar.2017.00081

Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, Garcia J, Guzmán M, Velasco G (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular Cancer Therapeutics 10(1): 90–103. https://doi.org/10.1158/1535-7163.MCT-10-0688

UK Medicines Information (2018) UK Medicines Information: Cannabis – based medicinal products. https://www.sps.nhs.uk/articles/about-ukmi-medicines-qas/

Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A, Sánchez C, Galve-Roperh I, Guzmán M (2007) Cannabinoids and gliomas. Molecular Neurobiology 36: 60–67. https://doi.org/10.1007/s12035-007-0002-5

Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ (2000) Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. Journal of Experimental Medicine 192: 1001–1014. https://doi.org/10.1084/jem.192.7.1001

Zou S, Kumar U (2018) Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences; 19(3): 1–833. https://doi.org/10.3390/ijms19030833

Welch DR, Hurst DR (2016) Beyond the Primary Tumor: Progression, Invasion, and Metastasis. The Molecular Basis of Human Cancer: 203–216. https://doi.org/10.1007/978-1-59745-458-2_12

WHO (2017) Cannabidiol (CBD). Pre-Review Report Agenda Item 5.2. Thirty-ninth Meeting Expert Committee on Drug Dependence, Geneva (Switzerland), November 2017.

Yamreudee Wong W, Wong HK, Brausch LM, Pulley KR (2009) Probable interaction between warfarin and marijuana smoking. Annals of Pharmacotherapy 43: 1347–1353. https://doi.org/10.1345/aph.1M064

Zhelyazkova M, Hadjimitova V, Hristova-Avakumova N (in press) Antioxidant and prooxidant properties of artemisinin and epirubicin in vitro biophysical models. Bulgarian Chemical Communications 51(Special Issue A).

Zou S, Kumar U (2018) Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences; 19(3): 1–833. https://doi.org/10.3390/ijms19030833